Researchers reported that CLN8—mutated in Batten disease—acts as a stereospecific acyltransferase involved in producing a lysosomal lipid central to cellular recycling. The work published in Nature Cell Biology ties a long-standing mechanistic gap to a defined enzymatic role, improving the biological map of how CLN8 loss disrupts lysosomal function. The findings connect neurodegeneration biology to specific lipid pathway steps, opening more direct paths for therapeutic target validation and potential pathway-correcting approaches. As with many rare neurodegenerative disorders, defining the precise substrate and reaction helps sharpen biomarker development. For drug developers, CLN8’s role also strengthens the case for looking beyond symptom management toward intervention at the level of lipid homeostasis.